by According to a research report “Over the Counter (OTC) Drugs Market (By Product Type: Analgesics, Cold & Cough Remedies, Digestives & Intestinal Remedies, Skin Treatment, Vitamins & Minerals, Others; By Distribution Channel: Drug Stores & Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030″ published by Precedence Research.
-Drugs-Market-Size-2020-to-2030.jpg "Over the Counter (OTC) Drugs Market Size 2020 to 2030")
The over the counter drugs market size is projected to hit from USD 171.47 billion in 2022 to USD 294.18 billion by 2030, growing at a CAGR of 6.9% every year.
The study provides an analysis of the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2021 is considered as the base year.
The non-prescription medicines are sometimes known as over the counter (OTC) drugs because they are available without a prescription. If taken as directed by a healthcare practitioner, over the counter (OTC) drugs are safe. The growth in awareness of general health problems, as well as innovations in the healthcare and pharmaceutical industries, is driving the growth of over the counter (OTC) drugs market. In addition, an increasing trend among individuals to use over the counter (OTC) drugs for mild ailments contributes towards the growth of over the counter (OTC) drugs market during the forecast period.
Get a Free Sample Copy of this Report@ https://www.precedenceresearch.com/sample/1466
Table of Contents
Scope of the Over the Counter (OTC) Drugs Market
| Report Coverage | Details |
| Market Size In 2020 | US$ 150.8 Billion |
| Growth Rate | CAGR of 6.9% from 2021 to 2030 |
| Revenue Projection by 2030 | US$ 294.18 Billion |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
Over the Counter Drugs Market Report Highlights
- Based on the product, the cold and cough remedies segment dominated the global over the counter (OTC) drugs market in 2020 with highest market share. The increase in geriatric population and rise in number of cold and cough cases is propelling the growth of segment during the forecast period.
- Based on the distribution channel, the drug stores and retail pharmacies segment is estimated to be the most opportunistic segment during the forecast period. The increase in number of retail stores or drug stores is driving the growth of the segment during the forecast period.
Over the Counter Drugs Market Dynamics
Drivers – Growing geriatric population
The population of old or senior people are growing on a large scale. According to World Health Organization (WHO), the number of people of age 65 years or above is expected to grow around 1.5 billion in 2050. The number is expected to rise in developing countries such as China, Japan, India, and South Korea. The geriatric population faces various kinds of health problems such as cancer, diabetes, high blood pressure, and blood sugar levels.
They need to be more careful with their health. So, they require medicines at certain interval of time. Sometimes, the geriatric people buy medicines without any kind of prescription. As a result, the growing geriatric population is driving the growth of over the counter (OTC) drugs market during the forecast period.
Restraints – Threat to life of people
The over the counter (OTC) drugs are non-prescribed medicines. The people who have little knowledge about drugs and medicines, consume medicines without consulting doctor or healthcare professional. This can have ill-effects on the health of consumers. The consequences of this action can also have threat on the drug stores and pharmacies.
Many incidences have been noticed where people have died by consuming wrong drugs or medicines. To avoid such situations, the over the counter (OTC) drugs need to be banned. Thus, the threat to life of people is a restricting factor for the growth of the over the counter (OTC) drugs market during the forecast period.
Read Also: Biofuels Market Predicted to Garner a Revenue of US$ 201.21 Bn By 2030
Opportunities – Rising awareness of general health problems
After COVID-19 pandemic, the people are more concerned towards their health. The consumption patterns have changed due to coronavirus outbreak. This has created new growth opportunities for the over the counter drugs in the market. Before a decade, the people were not aware about the causes of cold and cough. But after the pandemic the people have understood the importance of good health.
Many of the consumers have knowledge of medicines that can be consumed during certain health issues. As a result, the rising awareness of general health problems is paving the way for the growth of over the counter drugs market during the forecast period.
Challenges – Stringent government regulations
The sale of over the counter drugs in some regions is not legal. For this, certain rules and laws need to be followed. The Food and Drug Administration (FDA) has enacted certain regulatory framework that prohibits the use of over the counter drugs in the market. In many developed countries, the sale of over the counter drugs is banned. As a result, the stringent government regulations are a huge challenge for the growth of over the counter (OTC) drugs market during the forecast period.
Over the Counter Drugs Market Regional Snapshot
North America is the largest segment for over the counter drugs market in terms of region. The change in consumer lifestyle and growing preference of consumers towards over the counter drugs is expected to drive the growth of over the counter drugs market during the forecast period.
Europe region is the fastest growing region in the over the counter drugs market. Europe has large number of over the counter drugs manufacturers. This fact is resulting Europe region as one of the dominants in the over the counter drugs market.
Some of the prominent players in the global over the counter drugs market include:
- Bayer AG
- Takeda Pharmaceutical Company Ltd.
- Pfizer
- Johnson & Johnson Services Inc.
- Sanofi S.A.
- Reckitt Benckiser Group PLC
- Novartis AG
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline PLC
- Mylan
Segments Covered in the Report
By Product Type
- Analgesics
- Cold & Cough Remedies
- Digestives & Intestinal Remedies
- Skin Treatment
- Vitamins & Minerals
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- MEA
- Rest of the World
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Over the Counter (OTC) Drugs Market
5.1. COVID-19 Landscape: Over the Counter (OTC) Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Over the Counter (OTC) Drugs Market, By Product
8.1. Over the Counter (OTC) Drugs Market, by Product Type, 2021-2030
8.1.1. Analgesics
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Cold & Cough Remedies
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Digestives & Intestinal Remedies
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Skin Treatment
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Vitamins & Minerals
8.1.5.1. Market Revenue and Forecast (2019-2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Over the Counter (OTC) Drugs Market, By Distribution Channel
9.1. Over the Counter (OTC) Drugs Market, by Distribution Channel, 2021-2030
9.1.1. Drug Stores & Retail Pharmacies
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Hospital Pharmacies
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Over the Counter (OTC) Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2030)
Chapter 11. Company Profiles
11.1. Bayer AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Takeda Pharmaceutical Company Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Pfizer
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Johnson & Johnson Services Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Sanofi S.A.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Reckitt Benckiser Group PLC
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Boehringer Ingelheim International GmbH
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. GlaxoSmithKline PLC
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Mylan
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1466
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
